About Gate2Brain
Gate2Brain is a Healthcare company based in Barcelona (Spain) founded in 2019 by Esther Riambau, Gloria Sanclimens Perez De Rozas, and Marc Ramis Castelltort. It operates as a therapeutics delivery platform across biological barriers is developed. Gate2Brain has raised $8.12 million across 3 funding rounds from investors including European Union, EIC Fund and Shilpa Medicare. Gate2Brain offers products and services including G2B-002 and Peptide Shuttles Platform. Its focus areas include Life Sciences, Oncology, Drugs and Pediatric Cancer. Its legal entity is Gate2brain S.L. Its competitors include Ironwood Pharma, VeraDermics, Lipum, Proveca and Castle Creek Biosciences and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
A platform for delivering therapeutics across biological barriers, including the blood-brain barrier, is developed using patented peptide-based technology. The company was founded in 2019 and is based in Barcelona, Spain, within the biotechnology sector. Operations focus on creating treatments for central nervous system conditions, with the flagship product G2B-002 targeted at pediatric CNS tumors.
- Headquarters Barcelona, Spain
- Founders Esther Riambau, Gloria Sanclimens Perez De Rozas, Marc Ramis Castelltort
- SectorsHealthcare
- Email••••••••
- Website gate2brain.com
- Social LinkedIn YouTube
- Legal Name Gate2brain S.L.
- Total Equity Funding$8.12M (USD)
in 3 rounds
- Latest Funding Round$8.12M (USD), Series A
Jun 2026
- InvestorsEuropean Union
& 2 more
Products & Services of Gate2Brain
Gate2Brain offers a comprehensive portfolio of products and services, including G2B-002 and Peptide Shuttles Platform.
Drug for treating rare pediatric cancers by enhancing delivery across barriers
System for improving biopharmaceutical properties of various drug cargoes
Apps and channels of Gate2Brain
its YouTube channel Gate2Brain Biotech has 9 subscribers and 27 videos.
Videos from Gate2Brain
The most watched videos on Gate2Brain's YouTube channel, Gate2Brain Biotech (9 subscribers). Click a video to play it here.
More on Gate2Brain Biotech.
Funding Insights of Gate2Brain
Gate2Brain has successfully raised a total of $8.12M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $8.12 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.12M
- Total Rounds 3
- Last Round Series A — $8.12M
- First Round $2.81M
(Oct 2022)
- Investors Count 3
All 3 funding rounds of Gate2Brain with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $8.12M | Series A | – | – | |
| Aug 2023 | $82,240 | Grant | – | – | |
| Oct 2022 | $2.81M | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Gate2Brain
Gate2Brain has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, EIC Fund and Shilpa Medicare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
- | – | vbshilpa.com | - |
Investor details for Gate2Brain
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Gate2Brain
5 people are tracked at Gate2Brain (5 in leadership).
| Name | Role | Group |
|---|---|---|
Esther Riambau | Co-Founder | Leadership |
Gloria Sanclimens Perez De Rozas | Co-Founder | Leadership |
Marc Ramis Castelltort | Co-Founder | Leadership |
Meritxell Teixido | CEO/CSO | Leadership |
Gloria Sanclimens Pérez de Rozas | Product Development & Founder | Leadership |
Complete people profiles for Gate2Brain
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Gate2Brain
3 dated milestones of Gate2Brain across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Gate2Brain is founded.
- Funding First funding round of $2.8M.
- Funding Latest funding round, Series A, of $8.1M.
Competitors of Gate2Brain
Gate2Brain has 9 listed competitors in our database, 8 of them funded. They include Ironwood Pharma, VeraDermics, Lipum, Proveca and Castle Creek Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| veradermics.com | 2020 | San Antonio, United States | $262.71M | – | Drug-delivery platforms for pediatric wart treatments are developed. | |
| lipum.se | 2010 | Umea, Sweden | $2.99M | – | Developer of antibody to treat juvenile idiopathic arthritis | |
| proveca.com | 2010 | Manchester, United Kingdom | $8.45M | 23 | Medicines for chronic diseases in children are developed and provided. | |
| castlecreekbio.com | 2018 | Exton, United States | $192.8M | 41 | Gene therapy platform for rare disease treatments is developed. | |
| orphelia-pharma.eu | 2007 | Paris, France | $4.49M | – | Therapies for pediatric neurology, oncology, and hematology are developed. | |
| visenpharma.com | 2018 | Shanghai, China | $150M | 3 | Therapeutics for endocrine diseases are developed using TransCon technology. | |
| oncoheroes.com | 2017 | Brookline, United States | $9.95M | – | Therapies for pediatric cancer in children are discovered and developed. | |
| allievex.com | 2017 | Marblehead, United States | – | 7 | Developer of therapeutics for rare neurodegenrative diseases |
Detailed competitors of Gate2Brain
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pediatrics
10 companies that operate in the same segment as Gate2Brain (Pediatrics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Owlet is recognized for developing FDA-cleared smart baby monitors. | 2013 | Lehi, Utah, United States | USD 54.96 M | USD 105.71 M | 85 | |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Smart baby monitors and sleep tracking solutions are provided. | 2014 | New York, New York, United States | USD 116.6 M | – | – | |
Provider of diagnostic products for pediatrics | 2013 | Durham, North Carolina, United States | USD 95.89 M | – | – | |
Eye-tracking solutions for vision assessment and treatment are provided. | 2016 | Lod, Central District, Israel | USD 8 M | – | – | |
Patient vital signs are monitored via wearable devices and software. | 2018 | Niles, Illinois, United States | USD 71 M | – | – | |
Pediatric orthopedic devices are developed for surgical applications. | 2006 | Warsaw, United States | USD 51.55 M | USD 236.35 M | 562 | |
Gene therapy platform for rare disease treatments is developed. | 2018 | Exton, Pennsylvania, United States | USD 192.8 M | – | 41 | |
Pediatric cardiac surgical devices are developed for congenital heart defects. | 2011 | Pittsburgh, Pennsylvania, United States | USD 22.56 M | – | – | |
Drug-delivery platforms for pediatric wart treatments are developed. | 2020 | San Antonio, Texas, United States | USD 262.71 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Gate2Brain
Gate2Brain was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Gate2Brain is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Gate2Brain is a funded company, having raised a total of $8.12M across 3 funding rounds to date. The company's 1st funding round was a Grant of $2.81M, raised on Oct 2022.
A platform for delivering therapeutics across biological barriers, including the blood-brain barrier, is developed using patented peptide-based technology. The company was founded in 2019 and is based in Barcelona, Spain, within the biotechnology sector. Operations focus on creating treatments for central nervous system conditions, with the flagship product G2B-002 targeted at pediatric CNS tumors.
Gate2Brain's top competitors include Ironwood Pharma, Castle Creek Biosciences and VeraDermics.
Gate2Brain offers G2B-002 and Peptide Shuttles Platform.
Gate2Brain has 3 investors. Key investors include European Union, EIC Fund, and Shilpa Medicare.
Gate2Brain operates through Gate2brain S.L..